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Sm_mary The combination of mitozantrone, methotrexate and mitomycin (3M) gives a response rate of
around 50% in patients with advanced breast cancer. The predominant toxicity is haematological. In this
study, previously untreated patients were given 3M with increasing doses of mitozantrone (7-14 mg m-) with
recombinant human granulocyte colony-stimulating factor (metHuG-CSF) (filgrastim) to prevent marrow
toxicity. Doses administered were 7 mg m2 mitomycin i.v. 6 weekly, methotrexate i.v. 35 mg m-2 (maximum
50mg) 3 weekly and mitozantrone i.v. 3 weekly as follows: 7mgm-2, six patients (group 1); 10mgm-2, siX
patients (group 2); 12 mg m-2, six patients (group 3); 14 mg m-2, six patients (group 4); all on day I for six
cycles at the assigned dose. All patients received filgrastim (Amgen 0.3 mgml-') at a dose of 5zg kg-'
subcutaneously daily on days 4-17 of each cycle. All treatment was given on an out-patient basis. A total of
24 patients were entered into the study. The median age was 63 years (range 48-75). ECOG performance
status was 0 in ten, I in 11 patients and 2 in three patients. Locoregional disease alone was present in seven
patients. The remainder had one or more sites of metastases. The actual dose administered to the 24 patients
was as follows. The six patients in group 1 all completed six courses of treatment as per protocol. In group 2,
three patients completed six courses, two stopped because of toxicity after one and four courses and one had
progressive disease after one course. In group 3, three patients completed and three stopped early because of
progressive disease. In group 4, two patients completed, one progressed after four courses and three
responding patients stopped treatment because of toxicity. The maxiimum tolerated dose of mitozantrone in
the 3M combination was 12 mg m-2. The use of filgrastim with increasing doses of chemotherapy prevents
neutropenia, but other toxicities, namely thrombocytopenia and lethargy, then become dose limiting.
Many centres have returned to the concept of high-dose
therapy as consolidation in breast cancer using mobilised
peripheral stem cells as rescue for the marrow toxicity. The
results of randomised studies are not yet available, but these
are being carried out in patients with metastatic breast cancer
and in the high-risk adjuvant setting (Peters, 1993). High-
dose therapy in all tumour types has become a less toxic
procedure with a mortality rate of around 4% owing to the
use of penrpheral stem cell rescue instead of autologous bone
marrow rescue (Shenrdan et al., 1992).
High-dose chemotherapy with bone marrow support is not
a new concept in breast cancer. A phase II study reported in
1982, in which patients with metastatic breast cancer under-
went remission consolidation using high-dose melphalan,
showed no advantage in terms of relapse-free survival or
overall survival when compared with historical controls (Vin-
cent et al., 1988). High-dose chemotherapy as consolidation
of remission is one form of dose intensity. Another approach
is to deliver high doses of individual courses with growth
factor support. This would maximise drug exposure at the
time of large tumour burden and lead to rapid cell death and
response. This rapid elimination of tumour cells could pre-
vent the dissemination of micrometastases and decrease the
chance of drug resistance emerging. This concept would be
directly applicable to primary medical therapy for locally
advanced, inoperable, non-metastatic cancer or indeed to
early breast cancer for rapid downstaging (Smith et al.,
1992). Any other advantage for primary medical treatment
awaits the results of randomised clinical trials which are
currently being carried out.
The combination of mitozantrone, methotrexate and
mitomycin (3M) is now extensively used in all stages of
breast cancer. The 3M regimen has become popular mainly
because of the easy 3 weekly administration schedule and it
had equal activity to the anthrocycine-containing regimen
VAC in a randomised trial (Powles et al., 1991). In that
study the response rates for both regimens were around 52%.
The toxicity of 3M was acceptable, with 8% of patients (2%
of courses) developing grade IV leucopenia.
Recombinant metHuG-CSF (filgrastim) is a glycoprotein
which, in combination with other human colony-stimulating
factors, controls myeloid haematopoiesis. Its main toxicities
are musculoskeletal pain and changes in liver function
parameters. The major study establishing the efficacy of
filgrastim is a randomised trial performed in small-ell lung
cancer. Patients receiving the growth factor had a statistically
significant reduction in febrile neutropenic events, hos-
pitalisation and antibiotic requirements. They had a sig-
nificant reduction in the incidence and duration of severe
neutropenia, and in the time to recovery from neutropenia
(Crawford et al., 1991).
Traditionally, new approaches to treatment are tested in
the phase I/II setting in patients with metastatic disease.
Although toxicity data are fairly reliable, these are patients
with inherently resistant disease in whom small benefits in
terms of response rate and survival will not be detected. In
general, these patients have a poor performance status and
are not very resilient to aggressive treatment.
In this report we summarise the results of a phase I study
of the 3M combination given with increasing doses of
mitozantrone with filgrastim to ameliorate the anticipated
myelosuppression.
Materials and methods
Patients with advanced breast cancer previously untreated
with chemotherapy or radiotherapy (apart from adjuvant),
good ECOG performance status (<2) and life expectancy of
at least 3 months who gave informed written consent accord-
ing to the Royal Marsden Hospital Ethics Committee
guidelines were entered into the study. All patients had nor-
mal renal and liver function prior to treatment. Patients had
good bone marrow reserve as assessed on blood counts and
asymptomatic bone marrow involvement was not sought. All
treatment was given in the out-patient setting.
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The 3M combination was mitomycin 7 mg m-2 i.v. 6
weekly, methotrexate 35 mg m-2 (maximum 50 mg) i.v. 3
weekly and mitozantrone i.v. 3 weekly as follows: 7 mgm-2,
six patients (group 1); 10 mg m2, six patients (group 2);
12mgm2, six patients (group 3); 14mg m2, six patients
(group 4); all on day 1 for six cycles at the assigned dose. All
patients received filgrastim at a dose of 5 g kg-k' sub-
cutaneously daily on days 4-17 of each cycle. Patients were
allowed to self-administer the filgrastim if they were able to
after instruction. Alternatively, the district nurse provided the
service. Compliance was assessed by return of all vials every
3 weeks. In addition, patients received folinic acid 15 mg
every 6 h starting 24 h after the methotrexate injection and
continuing for a total of six doses. Standard prophylactic
antiemetics were given using dexamethasone 8 mg i.v. and
metoclopramide 20 mg i.v. with oral dexamethasone and oral
metoclopramide to take home for 3 days.
The peripheral blood count was checked weekly and before
each course, and treatment was delayed by 1 week if the
absolute neutrophil count (ANC) was <1.0 x 10-' 1 and
filgrastim was continued. If after 1 week's delay the ANC
was still < 1.0 x 109 1-', treatment was stopped but filgrastim
continued until the ANC recovered to > 1.0 x 10 1-'. If the
platelet count was <80 x 1091- at day 21, chemotherapy
was delayed by 1 week and if still <80 x 109 1-' at day 28,
the patient was withdrawn from the study. Biochemistry,
liver function tests and serum creatinine were assessed every
3 weeks. Left ventricular ejection fraction was measured by a
multigated cardiac scan before and after therapy as an
indicator of cardiac toxicity on patients in groups 3 and 4.
Objective response was assessed after three courses using
UICC criteria (Hayward et al., 1977).
Rests
A total of 24 patients were entered into the study. Patient
characteristics are presented in Table I. The median age was
63 years (range 48-75). ECOG performance status was 0 in
ten, 1 in 11 patients and 2 in three patients. Locoregional
disease alone was present in seven patients. The other 17
patients had one or more sites of metastases: seven patients
had nodal disease, six had lung involvement, six liver, 11
bone and four other sites (other breast in one patient,
mesenteric nodes in one and skin deposits in two patients).
No patient had received previous chemotherapy, but eight
patients had received adjuvant tamoxifen, one patient
adjuvant aminogluthemide and 18/24 patients had received at
least one form of hormone therapy for metastatic disease.
The median disase-free interval from initial diagnosis until
entry into this trial was 26 months (range 0-237). Three out
of 22 patients had an oestrogen receptor level of >20 fmol;
all the others had either a negative or unklnown value.
All patients were evaluable for toxicity and response. The
actual number of courses of treatment administered to the 24
patients was as follows (Table II). The six patients in group 1
all completed six courses of treatment as per protocol. In
group 2, three patients completed six courses, one stopped
because of toxicity (nausea and vomiting) after one course
and two patients progressed after four courses. In group 3,
three patients completed the study treatment and three
patients stopped because of progressive disease, one each at
two, three and four cycles. In group 4, two patients com-
pleted the study, one patient developed progressive disease
after four cycles, three responding patients stopped treatment
because of toxcicity, two refused fuirthr treatment because of
subjective toxicity, namely lethargy, after three and five
cycles and one patient stopped after five courses because of
persistent thrombocytopenia.
Patients attended weekly for blood counts and compliance
for attendance was 84% in group 1, 80% in group 2, 96% in
group 3 and 79% in group 4. Compliance was decreased in
groups I and 4 because of three patients who did not attend
for interim blood analyses. The medians and ranges for the
Table I Patient characteristics
Median age (years)
Disease-free interval
0 months
<24
24-48
48+
Menopause
Pre
Post
Oestrogen receptor
Unknown
Negative
Positive
Previous adjuvant therapy
Tamoxifen
Aminogluthemide
Chemotherapy
Number of previous hormone treatments
for metastatic disease
0
1°
2
3
4
Performance status
0
2
Sites of disease
Local
Nodal
Bone
Lung
Liver
Other
Number of sites
One
Two
Three
Four
63 (range 48-75)
10
6
7
4
20
17
4
3
8
1
0
6
11
3
1
3
10
11
3
17
7
11
6
6
4 (one other breast,
one mesentery,
two skin)
9
7
3
5
Table H Treatment deivered and reasons for stopping
Group
Course 1 2 3 4
1 6/6 6/6k 6/6 6/6
2 6/6 5/6 6/6b 6/6
3 6/6 5/6 5/6b 6/6k
4 6/6 5/6b 4/6b 5/6b
5 6/6 3/6 3/6 4/&'
6 6/6 3/6 3/6 2/6
aStoppedbecauseoftoxicity. bStoppedbecauseofprogressivedisease
*One patient tTwo patients.
total white celi count (WCC), ANC, percentage neutrophil
count, platelets and haemoglobin (Hb) were similar between
all courses within individual patients and between the four
levels. Figure 1 and Table Ill show the mean values of the
leucocyte counts during the study period. There were only
three documented episodes of a leucocyte count of < I x
I 1PI-': one after course 1 in group 3 and two episodes after
the fourth course in groups 3 and 4. Two patients in group 3
had a 1 week treatment delay because of leucopenia of
<3 x 1091-'. Other treatment delays were for either social
reasons or non-haematological toxicity - one patient with
stomatitis in group 1, three patients had a delay because of a
holiday, one in each of groups 2, 3 and 4. In group 4 one
patient had a delay because of influenza, one failed to attend
and one patient had a gastrointtinal bleed.982 M.E.R. O'BRIEN et al.
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0
x
0
0
0
0
C-)
30
20
10
5
3
2
Day 0 7 14 0 7 14 0 7 14 0 7 14 0 7 14 0 7 14 21
Course 1 2 3 4 5 6
Fugwe 1 Mean WBC during treatment. *, Group 1; U, group
2; A. group 3; *. group 4.
Table III Haematological toxicity: mean neutrophil range ( x I09 1')
by group
Day 1 2 3 4
7 5-9 3-5 3-12 2-12
14 12-38 13-36 7-25 9-35
21 4-10 4-6 4-8 4-7
Table IV Non-haematological toxicity by WHO grade
Grade 0 1 2 3
Stomatitis 13 7 2 2
Conjunctivitis 20 1 3 0
Lethargy 1 8 11 4
Infections 20 2 2 0
Alopecia 8 4 4 8
Nausea and vomiting 6 5 8 5
Constipation 21 3 0 0
Diarrhoea 18 5 1 0
Neuropathy 21 2 1 0
The mean platelet counts are shown in Figure 2. The
platelet count was <50 (29 and 26) at day 14 on two
occasions in one patient after the third and fifth course of
chemotherapy respectively and this patient in group 4 had
prolonged thrombocytopenia eventually requinrng cessation
of therapy. Seven patients required a blood transfusion: three
in group 1, one in group 3 and three in group 4 (one patient
had a transfusion on two separate occasions). Mean haemo-
globin values are shown in Figure 3. There were four
episodes of infection in four patients, two minor and two
moderate (septicaemia without hypotension and chest infec-
tion). Two of the infections were at group 1 and the other
two were at levels 3 and 4.
The most frequent non-haematological toxicities are
reported in Table IV, and the most frequent of these are
shown according to dose of mitozantrone in Table V. The
main toxicities were nausea and vomiting, alopecia and
lethargy. In addition, two patients in groups 3 and 4 com-
plained of headache with the filgrastim injections, one patient
had pruritus and another developed a mild skin rash. One
patient in group 4 had a gastrointestial bleed and a deep
venous thrombosis after the third and fifth courses of
chemotherapy respectively. Nausea and vomiting occurred at
all doses of mitozantrone but was grade 3 in five patients.
Some degree of hair loss occurred in all levels, with half the
study population requiring a wig at doses above 10 mg m-2.
Lethargy was the main toxicity, and although it occurred at
all doses of mitozantrone it was the reason for stopping
treatment in 2/6 patients in group 4. This was unexplained
and was not due to anaemia or other cause on haemato-
logical or biochemical parameters. The lethargy resolved on
Day 0 7 14 0 7 14 0 7 14 0 7 14 0 7 14 0 7 14 21
Course 1 2 3 4 5 6
Fugwe 2 Mean platelet count during treatment. 0, Group 1; *.
group 2; A, group 3; 1, group 4.
CD
c
0
0
E
0
0
13
12
11
10
I'
I
U
-
0
. -P
7 14 0 7 14 0 7 14 0 7 14 0 7 140 7 14 21
Fugue 3 Mean haemoglobin during treatment. 0. Group 1; *.
group 2; A, group 3; *. group 4.
Table V Toxicity by WHO grade and dose level
Group
1 2 3 4
Lethargy grade
0 0 1 0 0
1 1 3 3 1
2 5 1 2 3
3 0 1 1 2
Nausea and vomiting grade
0 2 1 1 2
1 1 1 2 1
2 2 1 2 3
3 1 3 1 0
Alopecia grade
0 0 3 3 2
1 3 1 0 0
2 3 0 0 1
3 0 2 3 3
Table VI Responses
Group
1 2 3 4
Complete response 0 0 0 1
Partial response 4 2 2 1
No change I 1 0 2
Progressive disease 1 3 4 2
Response rate 10/24 = 42% (95% confidence intervals 21-65).
stopping treatment. There was no deterioration in cardiac
function.
The response rate was 10/24=42% (95% CI 21-65%):
nine partial remissions and one complete remission. Res-
ponses were seen at all levels (Table VI); the complete remis-
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sion was in a patient with bilateral breast masses. Responses
were also seen in nodal disease, lung, mesentery, bone and
skin metastases. There were four patients with stable disease
and ten with progressive disease. The median duration of
response in responding patients was 8.5 months (range 6-20
months).
This study aimed to find the maximum tolerated dose of
mitozantrone in the 3M combination using filgrastim to con-
trol myelosuppression. The prolonged but reversible throm-
bocytopenia seen in group 4 suggests that maximum
haematological tolerance had been reached. The non-
haematological toxicity seen was similar to that expected
with 3M at standard dose in terms of nausea and vomiting,
stomatitis, constipation, diarrhoea or neuropathy. There were
few serious infections but there was a high incidence of
alopecia, and severe lethargy is not usually seen with this
regimen (Powles et al., 1991).
As with other studies using increasing doses of chemo-
therapy with growth factor support, non-haematological tox-
icities became dose limiting; Bronchud et al. (1989) used
doses of doxorubicin up to 150 mg m-2 and found epithelial
toxicity to be dose limiting in patients with advanced breast
cancer - this was an unpredicted and unusual syndrome
involving the skin of the palms and soles. In our study
lethargy proved to be the dose-limiting toxicity. It was pro-
found and constant, and for that reason two patients at the
higher dose of mitozantrone refused to continue treatment.
The symptom slowly regressed over a period of 6 weeks on
stopping treatment.
The maximum tolerated dose of mitozantrone was
12 mg m-2 in combination with mitomycin C and methotrex-
ate. This is not as high as has been achieved in other
combinations. Doses of mitozantrone up to 23mgm2 in
combination with cyclophosphamide and 5-fluorouracil have
been successfully administered with filgrastim support. At the
maximum dose the limiting factor was still neutropenia
(Catimel et al., 1992).
With intensive chemotherapy it is important to find com-
binations of drugs that are suited to dose escalation, and it
appears that the 3M combination is not the most suited to
this. Although the number of patients in this phase I study is
small, the response rate was noted to be in the range
achieved with the 3M combination (Powles et al., 1991) and
there was no evidence of a dose-response effect. In addition,
the median duration of response was around 8 months, a
figure that is achieved with most regimens for advanced
disease. This suggests that patients with metastatic disease
remain incurable and that current methods of dose escalation
will do little to change the natural history of this stage of
disease. In addition, although metastatic patients are often
treated with novel agents to document toxicity and efficacy,
the results may in fact be misleading as this group of patients
tolerate treatment poorly and have inherently resistant
disease. However, it will be ethically difficult to find any
alternative strategy.
The study was supported by the Cancer Research Campaign.
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